首页> 外文期刊>International Journal of Nanomedicine >Improvement of effect of water-in-oil microemulsion as an oral delivery system for fexofenadine: in vitro and in vivo studies
【24h】

Improvement of effect of water-in-oil microemulsion as an oral delivery system for fexofenadine: in vitro and in vivo studies

机译:改善油包水微乳作为非索非那定的口服给药系统的效果:体外和体内研究

获取原文
           

摘要

Abstract: Fexofenadine (FEX) has high solubility and low permeability (BCS, Class III). In this work, novel FEX loaded water in oil microemulsion (w/o) was designed to improve bioavailability and compared with Fexofen? syrup in in vitro and in vivo studies. In addition, pharmacokinetic parameters in permeability studies were estimated by using WinNonLin software program. w/o microemulsion system was optimized using a pseudoternary phase diagram, composed of span 80/lutrol F 68 (9.5:0.5 w/w), oleic acide, isopropyl alcohol and water as surfactant mixture; oil and cosurfactant was developed for oral drug delivery. w/o microemulsion systems were characterized by phase behavior, particle size, viscosity and solubilization capacity. In vitro studies were studied using Caco-2 cell monolayer. Pharmacokinetic parameters of w/o microemulsion were investigated in rabbits and compared to Fexofen? syrup. Fexofen? syrup and microemulsion were administered by oral gavage at 6 mg/kg of the same concentration. The experimental results indicated that microemulsion (HLB = 5.53) formed nanometer sized droplets (33.29 ± 1.76) and had good physical stability. This microemulsion increased the oral bioavailability of FEX which was highly water-soluble but fairly impermeable. The relative bioavailability of FEX microemulsion was about 376.76% compared with commercial syrup in rabbits. In vitro experiments were further employed for the enhanced effect of the microemulsion for FEX. These results suggest that novel w/o microemulsion plays an important role in enhancing oral bioavailability of low permeability drugs.
机译:摘要:非索非那定(FEX)具有高溶解度和低渗透性(BCS,III类)。在这项工作中,设计了新型FEX加载油微乳状液中的水(w / o)以提高生物利用度,并与Fexofen?进行了比较。糖浆的体外和体内研究。另外,通透性研究中的药代动力学参数是通过使用WinNonLin软件程序估算的。使用拟三元相图优化w / o微乳液体系,该相图由跨度80 / lutrol F 68(9.5:0.5 w / w),油酸,异丙醇和水作为表面活性剂混合物组成;开发了油和辅助表面活性剂用于口服药物递送。 w / o微乳液体系的特征在于相行为,粒度,粘度和增溶能力。使用Caco-2细胞单层研究了体外研究。对兔体内无乳状液的药代动力学参数进行了研究,并与非索芬芬进行了比较。糖浆。非索芬?通过口服管饲以相同浓度的6 mg / kg糖浆和微乳。实验结果表明,微乳液(HLB = 5.53)形成了纳米级液滴(33.29±1.76),并具有良好的物理稳定性。这种微乳剂增加了FEX的口服生物利用度,FEX的水溶性很高,但相当不渗透。与市售糖浆相比,FEX微乳剂的相对生物利用度约为376.76%。进一步采用体外实验来提高微乳对FEX的作用。这些结果表明,新型的无水微乳液在增强低渗透性药物的口服生物利用度中起重要作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号